Literature DB >> 6957244

HLA-DR monoclonal antibodies inhibit the proliferation of normal and chronic granulocytic leukaemia myeloid progenitor cells.

J M Goldman, J Hibbin, L Kearney, K Orchard, K H Th'ng.   

Abstract

We studied the capacity of murine monoclonal antibodies with HLA-DR specificity to inhibit the proliferation in vitro of erythroid (BFU-E and CFU-E) and granulocyte-macrophage (CFU-GM) progenitor cells in normal bone marrow and the blood of patients with chronic granulocytic leukaemia (CGL). Two IgG2 antibodies (CA 2.06 and L243) inhibited the proliferation of normal BFU-E and CFU-GM at relatively high dilution; a third antibody, DA2, had no effect on either progenitor cell. A complement-fixing monoclonal antibody with T-cell activity (OKT3) produced only minor reduction in progenitor cel proliferation. Further studies with L243 showed that BFU-E and CFU-GM from the blood of patients with CGL were inhibited to the same degree as normal marrow progenitor cells. The inhibition of progenitor cell proliferation by a given antibody was always complement dependent and was therefore presumed to be due to a direct cytotoxic effect. The inhibitory effect of monoclonal antibodies is a valuable approach to the characterization of antigenic determinants on myeloid progenitor cells and the differential cytotoxicity of selected monoclonal antibodies might be exploitable for therapy.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6957244     DOI: 10.1111/j.1365-2141.1982.tb03910.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  6 in total

1.  HLA-class II antigens on human hematopoietic progenitors.

Authors:  F W Busch; M Langer; G Pawelec; A Ziegler; P Wernet; H J Bühring; P Meyer; C Müller
Journal:  Blut       Date:  1987-03

2.  Novel immunogenic HLA-A*0201-restricted epidermal growth factor receptor-specific T-cell epitope in head and neck cancer patients.

Authors:  Pedro A Andrade Filho; Andrés López-Albaitero; William Gooding; Robert L Ferris
Journal:  J Immunother       Date:  2010-01       Impact factor: 4.456

3.  Quantitative expression and immunogenicity of MAGE-3 and -6 in upper aerodigestive tract cancer.

Authors:  Pedro A Andrade Filho; Andrés López-Albaitero; Liqiang Xi; William Gooding; Tony Godfrey; Robert L Ferris
Journal:  Int J Cancer       Date:  2009-10-15       Impact factor: 7.396

4.  Cytotoxicity of monoclonal antibodies against individually immunophenotyped human leukemic cells.

Authors:  M Beksac; A Porwit-Ksiazek; R Hast; P Biberfeld; P Reizenstein
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

5.  HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy.

Authors:  Ana Marcu; Leon Bichmann; Leon Kuchenbecker; Daniel Johannes Kowalewski; Lena Katharina Freudenmann; Linus Backert; Lena Mühlenbruch; András Szolek; Maren Lübke; Philipp Wagner; Tobias Engler; Sabine Matovina; Jian Wang; Mathias Hauri-Hohl; Roland Martin; Konstantina Kapolou; Juliane Sarah Walz; Julia Velz; Holger Moch; Luca Regli; Manuela Silginer; Michael Weller; Markus W Löffler; Florian Erhard; Andreas Schlosser; Oliver Kohlbacher; Stefan Stevanović; Hans-Georg Rammensee; Marian Christoph Neidert
Journal:  J Immunother Cancer       Date:  2021-04       Impact factor: 13.751

6.  Natural and cryptic peptides dominate the immunopeptidome of atypical teratoid rhabdoid tumors.

Authors:  Ana Marcu; Andreas Schlosser; Anne Keupp; Nico Trautwein; Pascal Johann; Matthias Wölfl; Johanna Lager; Camelia Maria Monoranu; Juliane S Walz; Lisa M Henkel; Jürgen Krauß; Martin Ebinger; Martin Schuhmann; Ulrich Wilhelm Thomale; Torsten Pietsch; Erdwine Klinker; Paul G Schlegel; Florian Oyen; Yair Reisner; Hans-Georg Rammensee; Matthias Eyrich
Journal:  J Immunother Cancer       Date:  2021-10       Impact factor: 13.751

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.